MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

Launched by BRIGHAM AND WOMEN'S HOSPITAL · Jun 9, 2020

Keywords

ClinConnect Summary

The MAP-HD trial is studying the effects of a medication called mannitol on blood pressure stability in adults who are undergoing hemodialysis and are prone to low blood pressure during treatment. This trial aims to see if mannitol can help improve symptoms and keep blood pressure in a safer range for patients who often experience drops in blood pressure during their dialysis sessions.

To participate in this trial, you must be at least 18 years old, have been on hemodialysis for more than 90 days, and have low blood pressure during at least 30% of your dialysis sessions in the last month. If you qualify, you will receive either mannitol or a placebo (a harmless substance with no active ingredients) during your dialysis sessions. The trial is currently looking for participants, and it’s important to know that certain health conditions, like recent heart attacks or strokes, may exclude you from joining. If you’re interested, you can discuss it with your healthcare provider to see if it’s a good fit for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Maintenance HD (\>90 days)
• • Age ≥18y
• • Thrice-weekly HD
• • IDH-prone (defined as nadir intra-dialytic SBP \<100 mmHg in ≥30% of sessions in the prior 4 weeks)
• • Hematocrit\>21%
• • Written informed consent
• Exclusion Criteria:
• • Acute myocardial infarction or stroke within one month
• • Pre-HD serum potassium \>6.5 mmol/L in last 4 weeks
• • Pregnancy
• • Institutionalized individuals
• • Life expectancy \<2 months
• • Planned renal transplant within 2 months
• • Active enrollment in another interventional trial
• • Known allergy to mannitol